Roche: FDA grants priority review to Roche's Gazyva/Gazyvaro for pMN
The decision is based on results from the Phase III MAJESTY study, which indicated that Gazyva/Gazyvaro achieved a higher rate of complete remission at two years compared to The post FDA grants priority review to Roche's Gazyva/Gazyvaro for pMN appeared first on Pharmaceutical Business review.
Read full article »
Roche is a Switzerland-based biotechnology company that discovers, develops, and provides diagnostic and pharmaceutical products and services for the healthcare sector.
Read more